BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reuland CJ, Church FC. Synergy between plasminogen activator inhibitor-1, α-synuclein, and neuroinflammation in Parkinson's disease. Med Hypotheses 2020;138:109602. [PMID: 32035284 DOI: 10.1016/j.mehy.2020.109602] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Hammerschmidt TG, Encarnação M, Lamberty Faverzani J, de Fátima Lopes F, Poswar de Oliveira F, Fischinger Moura de Sousa C, Ribeiro I, Alves S, Giugliani R, Regla Vargas C. Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA. Arch Biochem Biophys 2023;735:109510. [PMID: 36608914 DOI: 10.1016/j.abb.2023.109510] [Reference Citation Analysis]
2 Bartl M, Dakna M, Schade S, Otte B, Wicke T, Lang E, Starke M, Ebentheuer J, Weber S, Toischer K, Schnelle M, Sixel-Döring F, Trenkwalder C, Mollenhauer B. Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease. Mov Disord 2023;38:68-81. [PMID: 36267007 DOI: 10.1002/mds.29257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hu S, Li S, Ning W, Huang X, Liu X, Deng Y, Franceschi D, Ogbuehi AC, Lethaus B, Savkovic V, Li H, Gaus S, Zimmerer R, Ziebolz D, Schmalz G, Huang S. Identifying crosstalk genetic biomarkers linking a neurodegenerative disease, Parkinson's disease, and periodontitis using integrated bioinformatics analyses. Front Aging Neurosci 2022;14:1032401. [PMID: 36545026 DOI: 10.3389/fnagi.2022.1032401] [Reference Citation Analysis]
4 Seillier C, Lesept F, Toutirais O, Potzeha F, Blanc M, Vivien D. Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases. IJMS 2022;23:10336. [DOI: 10.3390/ijms231810336] [Reference Citation Analysis]
5 Church FC. Suggestions on leading an academic research laboratory group. Open Life Sciences 2022;17:599-609. [DOI: 10.1515/biol-2022-0061] [Reference Citation Analysis]
6 Xu Q, Lai Q, Wang J, Zhuang L, Cheng L, Mo Y, Liu L, Zhao Z, Zhang Y, Weng S, Qiao S. Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinson's disease in Chinese patients. Acta Neurol Belg 2021. [PMID: 34845645 DOI: 10.1007/s13760-021-01843-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Buzoianu AD, Sahib S, Tian ZR, Bryukhovetskiy I, Manzhulo I, Menon PK, Patnaik R, Wiklund L, Sharma A. Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Prog Brain Res 2021;265:1-97. [PMID: 34560919 DOI: 10.1016/bs.pbr.2021.04.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang H, Liu Y, Zhao J, Guo X, Hu M, Chen Y. Possible inflammatory mechanisms and predictors of Parkinson's disease patients with fatigue (Brief Review). Clin Neurol Neurosurg 2021;208:106844. [PMID: 34388595 DOI: 10.1016/j.clineuro.2021.106844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yepes M, Woo Y, Martin-Jimenez C. Plasminogen Activators in Neurovascular and Neurodegenerative Disorders. Int J Mol Sci 2021;22:4380. [PMID: 33922229 DOI: 10.3390/ijms22094380] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sillen M, Declerck PJ. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target? Int J Mol Sci 2021;22:2721. [PMID: 33800359 DOI: 10.3390/ijms22052721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
11 Segura-aguilar J. Parkinson's disease. Clinical Studies and Therapies in Parkinson's Disease 2021. [DOI: 10.1016/b978-0-12-822120-4.00001-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Wang M, Xie Y, Qin D. Proteolytic cleavage of proBDNF to mBDNF in neuropsychiatric and neurodegenerative diseases. Brain Res Bull 2021;166:172-84. [PMID: 33202257 DOI: 10.1016/j.brainresbull.2020.11.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
13 Wang Y, Wei N, Li X. Preclinical Evidence and Possible Mechanisms of Baicalein for Rats and Mice With Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Aging Neurosci 2020;12:277. [PMID: 33101006 DOI: 10.3389/fnagi.2020.00277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
14 Hall ME, Church FC. Exercise for Older Adults Improves the Quality of Life in Parkinson's Disease and Potentially Enhances the Immune Response to COVID-19. Brain Sci 2020;10:E612. [PMID: 32899958 DOI: 10.3390/brainsci10090612] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]